Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Gastric Signet-Ring Cell Carcinoma
Furkejuvvon:
| Publikašuvnnas: | Cancers vol. 17, no. 14 (2025), p. 2400-2416 |
|---|---|
| Váldodahkki: | |
| Eará dahkkit: | , , , , , , , , , , |
| Almmustuhtton: |
MDPI AG
|
| Fáttát: | |
| Liŋkkat: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3233104283 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2072-6694 | ||
| 024 | 7 | |a 10.3390/cancers17142400 |2 doi | |
| 035 | |a 3233104283 | ||
| 045 | 2 | |b d20250715 |b d20250731 | |
| 084 | |a 231438 |2 nlm | ||
| 100 | 1 | |a Sorrenti Salvatore |u Department of Surgery, “Sapienza” University of Rome, 00161 Roma, Italy; salvatore.sorrenti@uniroma1.it (S.S.); eleonora.lori@uniroma1.it (E.L.); daniele.pironi@uniroma1.it (D.P.) | |
| 245 | 1 | |a Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Gastric Signet-Ring Cell Carcinoma | |
| 260 | |b MDPI AG |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background: Gastric signet-ring cell carcinoma (GSRCC) is an aggressive gastric cancer subtype with limited evidence supporting the role of neoadjuvant chemotherapy (NAC). This study evaluated the impact of NAC on overall survival (OS) in a large, population-based cohort. Methods: We analyzed data from the SEER database (2011–2018), identifying patients aged 20–80 years with primary gastric tumors (C16.0–C16.9) and signet-ring cell histology who underwent curative-intent gastrectomy. Patients with metastatic disease, non-curative surgery, clinical Stage I, incomplete staging, or unknown survival were excluded. OS was assessed using Kaplan–Meier analysis and multivariable Cox regression. Subgroup analyses evaluated the interaction of NAC with tumor location and clinical stage. Results: A total of 978 patients met inclusion criteria; 436 (44.6%) received NAC. The 3- and 5-year OS rates were 43.9% and 38.3%, respectively. NAC was not associated with improved OS compared to surgery alone (5-year OS: 39.7% vs. 37.2%; log-rank p = 0.34) and was not an independent prognostic factor in multivariable analysis (p = 0.651). Independent predictors of worse OS included larger tumor size, advanced stage, positive nodal status, and Black race (all p < 0.05). Subgroup analysis indicated a survival benefit from NAC in patients with mid or distal gastric tumors (p < 0.001 for interaction). Conclusions: In this SEER-based analysis, NAC did not improve OS in the overall GSRCC population. However, selected subgroups may derive benefit, supporting a personalized approach to neoadjuvant therapy in GSRCC. | |
| 651 | 4 | |a United States--US | |
| 653 | |a Patients | ||
| 653 | |a Population | ||
| 653 | |a Gastrointestinal surgery | ||
| 653 | |a Histology | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Metastasis | ||
| 653 | |a Cancer therapies | ||
| 653 | |a Surgery | ||
| 653 | |a Variables | ||
| 653 | |a Gastrectomy | ||
| 653 | |a Tumors | ||
| 653 | |a Gastric cancer | ||
| 653 | |a Surveillance | ||
| 653 | |a Metastases | ||
| 653 | |a Chemotherapy | ||
| 653 | |a Population studies | ||
| 653 | |a Carcinoma | ||
| 653 | |a Decision making | ||
| 700 | 1 | |a Malerba, Silvia |u Department of Precision and Regenerative Medicine and Ionian Area, University of Bari “Aldo Moro”, 70110 Bari, Italy; s.malerba10@studenti.uniba.it (S.M.); francesco.prete@uniba.it (F.P.P.); mario.testini@uniba.it (M.T.) | |
| 700 | 1 | |a Eleonora, Lori |u Department of Surgery, “Sapienza” University of Rome, 00161 Roma, Italy; salvatore.sorrenti@uniroma1.it (S.S.); eleonora.lori@uniroma1.it (E.L.); daniele.pironi@uniroma1.it (D.P.) | |
| 700 | 1 | |a Pironi Daniele |u Department of Surgery, “Sapienza” University of Rome, 00161 Roma, Italy; salvatore.sorrenti@uniroma1.it (S.S.); eleonora.lori@uniroma1.it (E.L.); daniele.pironi@uniroma1.it (D.P.) | |
| 700 | 1 | |a Polom Karol |u Department of Medicine, Academy of Applied Medical and Social Sciences—AMiSNS (Akademia Medycznych I Spolecznych Nauk Stosowanych), 52-300 Elbląg, Poland; k.polom@amisns.edu.pl (K.P.); j.skokowski@amisns.edu.pl (J.S.); yogesh.vashist@outlook.de (Y.K.V.) | |
| 700 | 1 | |a Skokowski Jaroslaw |u Department of Medicine, Academy of Applied Medical and Social Sciences—AMiSNS (Akademia Medycznych I Spolecznych Nauk Stosowanych), 52-300 Elbląg, Poland; k.polom@amisns.edu.pl (K.P.); j.skokowski@amisns.edu.pl (J.S.); yogesh.vashist@outlook.de (Y.K.V.) | |
| 700 | 1 | |a Girnyi Sergii |u Department of General Surgery and Surgical Oncology, “Saint Wojciech” Hospital, “Nicolaus Copernicus” Health Center, 80-000 Gdańsk, Poland; sgirnyi@copernicus.gda.pl (S.G.); tcwalinski@copernicus.gda.pl (T.C.) | |
| 700 | 1 | |a Cwalinski Tomasz |u Department of General Surgery and Surgical Oncology, “Saint Wojciech” Hospital, “Nicolaus Copernicus” Health Center, 80-000 Gdańsk, Poland; sgirnyi@copernicus.gda.pl (S.G.); tcwalinski@copernicus.gda.pl (T.C.) | |
| 700 | 1 | |a Prete, Francesco Paolo |u Department of Precision and Regenerative Medicine and Ionian Area, University of Bari “Aldo Moro”, 70110 Bari, Italy; s.malerba10@studenti.uniba.it (S.M.); francesco.prete@uniba.it (F.P.P.); mario.testini@uniba.it (M.T.) | |
| 700 | 1 | |a Vashist, Yogesh K |u Department of Medicine, Academy of Applied Medical and Social Sciences—AMiSNS (Akademia Medycznych I Spolecznych Nauk Stosowanych), 52-300 Elbląg, Poland; k.polom@amisns.edu.pl (K.P.); j.skokowski@amisns.edu.pl (J.S.); yogesh.vashist@outlook.de (Y.K.V.) | |
| 700 | 1 | |a Testini Mario |u Department of Precision and Regenerative Medicine and Ionian Area, University of Bari “Aldo Moro”, 70110 Bari, Italy; s.malerba10@studenti.uniba.it (S.M.); francesco.prete@uniba.it (F.P.P.); mario.testini@uniba.it (M.T.) | |
| 700 | 1 | |a Marano Luigi |u Department of Medicine, Academy of Applied Medical and Social Sciences—AMiSNS (Akademia Medycznych I Spolecznych Nauk Stosowanych), 52-300 Elbląg, Poland; k.polom@amisns.edu.pl (K.P.); j.skokowski@amisns.edu.pl (J.S.); yogesh.vashist@outlook.de (Y.K.V.) | |
| 773 | 0 | |t Cancers |g vol. 17, no. 14 (2025), p. 2400-2416 | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3233104283/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/3233104283/fulltextwithgraphics/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3233104283/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |